A- A A+

Take Home Naloxone: best practice in preventing fatal opioid overdoses for prison leavers

(...) People leaving prison are at the highest risk of overdose and drug-related death in the first weeks following release. This is likely due to reduced tolerance to heroin, increased purity of drugs compared to those used in prison and the tendency of some released prisoners to return to previous drug use patterns.Increasing the uptake of Take Home Naloxone (THN) amongst opioid users leaving prison (and in the community) can help reduce the number of drug-related deaths amongst this high risk population. (The Forward Trust, UK, Pulse#7, Juni 2019)

https://www.forwardtrust.org.uk/media/1891/pulse-7-final.pdf

Pulmonary Complications of Opioid Overdose Treated With Naloxone.

Farkas A, Lynch MJ, Westover R, Giles J, Siripong N, Nalatwad A, Pizon AF, Martin-Gill C.

Ann Emerg Med. 2019 Jun 7. pii: S0196-0644(19)30309-9. doi: 10.1016/j.annemergmed.2019.04.006. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31182316

Naloxone interventions in opioid overdoses: a systematic review protocol.

Shaw LV, Moe J, Purssell R, Buxton JA, Godwin J, Doyle-Waters MM, Brasher PMA, Hau JP, Curran J, Hohl CM.

Syst Rev. 2019 Jun 11;8(1):138. doi: 10.1186/s13643-019-1048-y.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560883/

Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.

Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. 

JAMA Netw Open.Published online June 21, 20192(6):e196215. doi:10.1001/jamanetworkopen.2019.6215

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2736179

Naloxone urban legends and the opioid crisis: what is the role of public health?

Crabtree A, Masuda JR.

BMC Public Health. 2019 May 30;19(1):670. doi: 10.1186/s12889-019-7033-5.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543555/

Successful Naloxone Challenge Test in a Patient With Atrial Flutter.

Harlow TR, Peters JR, Anderson DL.

Prim Care Companion CNS Disord. 2019 May 23;21(3). pii: 18l02385. doi: 10.4088/PCC.18l02385.

https://www.psychiatrist.com/PCC/article/Pages/2019/v21n03/18l02385.aspx

Should we worry that take-home naloxone availability may increase opioid use?.

Tas, B., Humphreys, K., McDonald, R., and Strang, J. ( 2019) 

Addiction, doi.org/10.1111/add.14637.

https://onlinelibrary.wiley.com/doi/10.1111/add.14637

USA. Naloxone Has Made Overdosing Less Terrifying

Some drug users say that as long as the lifesaving drug is around, they don’t worry as much about dying. (The Atlantic, USA, 08.06.2019)

https://www.theatlantic.com/health/archive/2019/06/narcan-makes-fentanyl-overdoses-feel-safer-users/591217

Pharmacokinetic Interaction of Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.

Krieter PA, Chiang CN, Gyaw S, Skolnick P, Snyder R.

Drug Metab Dispos. 2019 Apr 16. pii: dmd.118.085977. doi: 10.1124/dmd.118.085977. 

http://dmd.aspetjournals.org/content/dmd/early/2019/04/16/dmd.118.085977.full.pdf

Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal.

Heaton JD, Bhandari B, Faryar KA, Huecker MR.

J Emerg Med. 2019 Apr 5. pii: S0736-4679(19)30121-0. doi: 10.1016/j.jemermed.2019.02.015. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30961922

USA. Allowing Pharmacists to Directly Dispense Opioid Antidote Can Sharply Cut Opioid Overdose Deaths

Allowing pharmacists to dispense the opioid antidote naloxone without a physician's prescription can sharply reduce the incidence of fatal opioid-related overdoses, according to a new RAND Corporation study.

States that adopted such laws saw fatal opioid overdoses fall by an average of 27 percent during the second year following passage and 34 percent in subsequent years, according to the study published in the journal JAMA Internal Medicine. (RAND, USA, 06.05.2019)

https://www.rand.org/news/press/2019/05/06.html

Does Take-Home Naloxone Availability Increase Opioid Use?.

Tas, B., Humphreys, K., McDonald, R., and Strang, J. ( 2019) 

Addiction, doi.org/10.1111/add.14637.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14637

USA. FDA approves first generic naloxone nasal spray to treat opioid overdose

Agency is also taking new steps to support development of over-the-counter and additional generics of naloxone to help reduce opioid overdose deaths, increase access to emergency treatment. (FDA – US Fodd and Drug Administration, 19.04.2019)

https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose

Evidence-Based Guidelines for EMS Administration of Naloxone.

Williams K, Lang ES, Panchal A, Gasper JJ, Taillac P, Gouda J, Hedges M.

Prehosp Emerg Care. 2019 Mar 29:1-41. doi: 10.1080/10903127.2019.1597955. 

https://www.tandfonline.com/doi/full/10.1080/10903127.2019.1597955

Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN® Nasal Spray and Naloxone Prefilled Syringe with Nasal Atomizer.

Tippey KG, Yovanoff M, McGrath LS, Sneeringer P.

Pain Ther. 2019 Mar 15. doi: 10.1007/s40122-019-0118-0. 

https://link.springer.com/article/10.1007%2Fs40122-019-0118-0

Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.

Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.

Neuropsychopharmacology. 2019 Mar 13. doi: 10.1038/s41386-019-0368-x. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30867551

Evaluation and optimization of take-home naloxone in an academic medical center.

Cooler J, Ross CA, Robert S, Linder L, Ruhe AM, Philip A.

Ment Health Clin. 2019 Mar 1;9(2):105-109. doi: 10.9740/mhc.2019.03.105.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398357/

USA. Next-generation single-dose antidotes for opioid overdoses.

American Chemical Society. (ScienceDaily, USA, 31.03.2019)

https://www.sciencedaily.com/releases/2019/03/190331192537.htm

Opioid Overdose Reversal News: FDA-approved naloxone devices produce substantially higher blood levels of naloxone than improvised nasal spray

(...) A new study looked at how well the FDA-approved nasal spray and autoinjector compared to the improvised nasal devices, which are not FDA-approved. Scientists found that the approved naloxone devices deliver higher blood levels of naloxone than the improvised nasal devices. In fact, levels in the plasma concentration of naloxone are considerably lower when improvised devices are used. The FDA-approved 4-mg dose nasal spray produced the highest blood level of naloxone of all the products tested. (NIDA, USA, 15.03.2019)

https://www.drugabuse.gov/news-events/news-releases/2019/03/opioid-overdose-reversal-news-fda-approved-naloxone-devices-produce-substantially-higher-blood

Heroin body-packing and naloxone

Vahabzadeh, Maryam et al.

The Lancet , Volume 393 , Issue 10177 , e35 

(Registrierung erforderlich)

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30502-1/fulltext

The effects of heat and freeze-thaw cycling on naloxone stability

Dulcie Lai, Amy Trinh Pham, Praveen P. Nekkar Rao and Michael A. Beazely 

Harm Reduction Journal 2019, 16:17, doi.org/10.1186/s12954-019-0288-4

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0288-4

Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal.

Overbeek DL, Abraham J, Munzer BW.

Clin Pract Cases Emerg Med. 2019 Jan 4;3(1):24-26. doi: 10.5811/cpcem.2018.11.40588.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366391/

A novel naloxone training compared with current recommended training in an overdose simulation.

Franko TS 2nd, Distefano D, Lewis L.

J Am Pharm Assoc (2003). 2019 Feb 8. pii: S1544-3191(18)30590-9. doi: 10.1016/j.japh.2018.12.022.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30745190

Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.

Phillips RH, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A.

Ann Emerg Med. 2019 Feb 14. pii: S0196-0644(19)30006-X. doi: 10.1016/j.annemergmed.2019.01.006.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30773411

Higher doses of naloxone are needed in the synthetic opiod era

Ronald B. Moss and Dennis J. Carlo

Substance Abuse Treatment, Prevention, and Policy, 2019, 14:6, doi.org/10.1186/s13011-019-0195-4

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-019-0195-4

USA. FDA may recommend overdose reversal drug alongside opioid prescriptions

In a growing number of states, patients who get opioids for serious pain may leave their doctors' offices with a second prescription -- for naloxone, a drug that can save their lives if they overdose on the powerful painkillers. (CNN, USA, 20.02.2019)

https://edition.cnn.com/2019/02/20/health/opioids-naloxone-prescriptions-partner/index.html

Pharmacokinetics of a novel, approved, 1.4 mg intranasal naloxone formulation for reversal of opioid overdose - a randomised controlled trial.

Skulberg AK, Åsberg A, Khiabani HZ, Røstad H, Tylleskar I, Dale O.

Addiction. 2019 Jan 14. doi: 10.1111/add.14552.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30644628

Take-home naloxone: a life saver in opioid overdose

The Lancet , Volume 393 , Issue 10169 , 296 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30153-9/fulltext

Scotland's National Naloxone Programme

Bird, Sheila M et al.

The Lancet , Volume 393 , Issue 10169 , 316 - 318 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33065-4/fulltext

USA. FDA Takes Step to Allow Drug Companies to Sell Naloxone Without Prescription

USA. FDA Takes Step to Allow Drug ComThe U.S. Food and Drug Administration (FDA) has taken a step to make it easier for companies that make the opioid overdose antidote naloxone to sell the drug without a prescription, CNBC reports. Making naloxone available over-the-counter would lower costs and increase consumer access, the agency said. (drugfree.org, USA, 24.01.2019)

https://drugfree.org/learn/drug-and-alcohol-news/fda-takes-step-to-allow-drug-companies-to-sell-naloxone-without-prescription